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Background/Aims:  Liver biopsy is a standard method for diagnosis of liver cirrhosis in patients with chronic hepatitis. Because 
liver biopsy is an invasive method, non-invasive methods have been used for diagnosis of compensated liver cirrhosis in patients 
with chronic hepatitis. The current study was designed to evaluate the usefulness of ultrasonography and routine blood tests for 
diagnosis of compensated liver cirrhosis in patients with chronic viral hepatitis. Methods: Two hundred three patients with chronic 
viral hepatitis who underwent liver biopsy were included in this study and ultrasonography and routine blood tests were analyzed 
retrospectively. Ultrasonographic findings, including surface nodularity, parenchyma echogenecity, and spleen size, were 
evaluated. The diagnostic accuracy of ultrasonography and routine blood tests were examined. Results: Discriminant analysis 
with forward stepwise selection of variables showed that liver surface nodularity, platelet count, and albumin level were 
independently associated with compensated liver cirrhosis (p<0.05). Cross-tabulation revealed that the following 4 variables had 
>95% specificity: platelet count <100,000 /uL; albumin level <3.5 g/dL; INR >1.3; and surface nodularity. If at least one of the four 
variables exists in a patient with chronic viral hepatitis, we can predict liver cirrhosis with 90% specificity and 61% sensitivity. 
Conclusions:  These results suggest that four variables (platelet count <100,000 /uL, albumin level <3.5 g/dL, INR >1.3, and 
surface nodularity) can be used for identification of liver cirrhosis in patients with chronic viral hepatitis with high specificity. 
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INTRODUCTION
Chronic hepatitis B (CHB) and C (CHC) are major causes of 
chronic hepatitis.
1 Chronic carriers of the hepatitis B virus (HBV) 
are currently estimated to number of 350 million worldwide.
2 
Chronic carriers of hepatitis C virus (HCV) are estimated to 
number approximately 170 million people.
3 Chronic hepatitis 
can progress to compensated liver cirrhosis. Compensated liver 
cirrhosis may then progress to liver failure and hepatocellular 
carcinoma  with  attendant  complications,  such  as  hepatic 
encephalopathy and varix bleeding. Therefore, early detection of 
liver cirrhosis in patients with chronic hepatitis has become an 
important clinical issue for physicians.
4,5 Because the diagnosis 
of liver cirrhosis requires histologic demonstration of abnormal 
regenerative nodules surrounded by fibrosis, liver biopsy is still 
considered to be the gold standard for assessing fibrosis.
6 Liver 
biopsy is limited, however, by the invasiveness of the procedure, 
cost, risk of complications (pain, bleeding, pneumothorax, bile 
peritonitis, and perforation), poor acceptance by patients, availability 
of expert practitioners, and intra- and inter-observer variability. 
An overall mortality one of 1 person per 10,000 has been reported 
in patients undergoing liver biopsy. False negative probability 
due to sampling error is reported to be 20~30%.
6-9 
It is necessary to establish non-invasive diagnostic methods to 370  The Korean Journal of Hepatology Vol. 16. No. 4, December 2010
Table  1.  Baseline  characteristics  of  patients
　 Patients  (N=203)
Age,  years  37.37±1.3
Male/female,  n  (%) 167/36 (82.3/37.7)
Hepatitis  B/hepatitis  C,  n  (%) 156/47 (76.8/23.2)
ALT,  U/L  140.4±326.8
AST,  U/L  96.5±239.9
Total  bilirubin,  mg/dL  1.3±1.5
Hemoglobin,  g/dL  14.9±1.0
White  blood  cell  count,  /uL  5,948±1,575.1
Histology  F1-3/F4,  n  (%) 167/36 (82.3/37.7)
Values are expressed as the mean±SD for continuous variables 
and  number  (%)  for  categorical  variables.  Liver  histology  was 
evaluated semi-quantitatively according to the Metavir system.
14
ALT, alanine aminotransferase; AST, aspartate aminotransferase.
diagnose  liver cirrhosis  more easily.  Non-invasive  and more 
reproducible alternative methods, such as an elastography and 
blood indices, have been proposed and tested as a means for 
detection of liver cirrhosis, however, the clinical use is limited 
because those methods have not been confirmed and are difficult 
to use.
10-12 A liver biopsy is rarely performed in the clinical 
diagnosis of compensated cirrhosis, and compensated cirrhosis is 
usually diagnosed by using blood tests and abdominal ultrasonography. 
However, the diagnostic criteria for liver cirrhosis and accuracy 
of the tests may vary according to the hospital. The present study 
was  designed  to  determine  the  accuracy  of  abdominal 
ultrasonography and blood tests in the diagnosis of compensated 
cirrhosis in patients with CHB and CHC, and to determine the 




This retrospective study included 203 consecutive patients 
with CHB or CHC who underwent percutaneous liver biopsies, 
abdominal ultrasonography, and blood tests at Ajou University 
Hospital of Ajou University College of Medicine in Suwon, 
Korea between December 2003 and October 2009. Two hundred 
eighty patients underwent liver biopsies during the enrollment 
period. Seventy-seven patients were excluded because of poor 
quality ultrasonographic findings. Liver biopsies were performed 
to assess the degree of liver fibrosis and inflammation before 
antiviral treatment. Sonographic findings and blood tests were 
compared with histologic findings. 
The patients included 167 males and 36 females (156 patients 
with CHB and 47 patients with CHC) with a mean age of 
37.4  years  (range,  18~72  years).  Histologic  examination 
revealed 167 F0-3 and 36 F4 (Table 1). In this study, CHB was 
defined as positivity for serum hepatitis B surface antigen, and a 
serum alanine aminotransferase (ALT) and/or aspartate amino-
transferase (AST) level at least a 2-fold above the upper limit of 
normal for > 6 months. CHC was defined as positivity for serum 
anti-HCV antibody and HCV RNA. All of the patients were 
compensated  for  liver  function.  Exclusion  criteria  included 
autoimmune liver disease, evidence of alcoholic or fatty liver 
disease,  and  combined  positivity  for  other  hepatitis  virus 
markers and other spleen and gallbladder-related diseases. Blood 
tests were performed within 1 week of abdominal ultrasono-
graphy and included a complete blood count, routine chemistries, 
such as albumin and bilirubin, and blood clotting factors, such as 
the international normalized ratio (INR). 
Abdominal ultrasonography
Ultrasonography (US) examinations were performed within 1 
week of the liver biopsy by two physicians (S. W. C. and J. Y. C.) 
using Logiq 7 (General Electric Co., Tokyo, Japan) or Prosound 
SSD-5000SV (Aloka Co., Wisconsin, USA) equipped with a 
3.5~5.0  MHz  convex  probe.  Ultrasonographic  findings  were 
reviewed by two gastroenterologists (S. W. C. and J. Y. C.) and a 
radiologist  (J.  K. K.).  For  30 patients, the  inter-observer 
variability  of  the  US  findings  was  tested  to  improve  the 
objectivity of  ultrasonographic findings.  The  reviewers  were 
unaware of the pathologic diagnoses of the patients. 
The US score was graded using three US variables which have 
been reported to be associated with the presence of cirrhosis and 
are currently utilized in clinical practice. Liver boundaries were 
carefully  examined  on  the  inferior  surface  of  both  lobes, 
especially in relation to the gallbladder and right kidney, and 
distinguished  as  normal  (=0)  and  nodular  (=1).  Liver 
echogenecity  was  classified  as  normal  (=0),  coarse,  and 
irregular (=1) in relation to the echogenecity and distribution of 
parenchyma echoes. Spleen size was assessed by the longitudinal 
size as this variable has been demonstrated to correlate with the 
actual spleen volume and is considered normal up to 12 cm. Each 
variable was classified as normal (=0) or frankly pathologic (=1). 
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Table  2.  Area  under  the  curve  of  each  variable  for  compensated  liver  cirrhosis
Variables AUROC  (95%  CI) P-value
Platelet  0.798  (0.714~0.882) <0.001
Albumin 0.662  (0.566~0.758) 0.002
INR 0.684  (0.593~0.775) 0.001
Spleen  size 0.503  (0.405~0.600) 0.960
Surface  nodularity  0.802  (0.719~0.886) <0.001
Echogenecity  0.750  (0.671~0.829) <0.001
AUROC,  areas  under  the  receiver-operating  characteristic  curves;  INR,  international  normalized  ratio.
Table  3.  Logistic  regression  analysis  of  each  variable  versus  pathologic  diagnosis  for  compensated  liver  cirrhosis 
Variables Correlation  coefficient Odds  ratio P-value
Platelet  (<100,000/uL)  0.989 2.687 0.228
Platelet  (<120,000/uL) 1.521 4.575 0.017
Albumin  (<3.5  g/dL) 2.518 12.409 0.013
INR  (>1.3)  1.404 4.072 0.134
Echogenecity 0.400 1.492 0.537
Surface  nodularity  2.537 12.645 0.001
Spleen  size  (>12  cm)  -1.603 0.345 0.245
INR,  international  normalized  ratio.
there is no adverse evidence suggesting different relevance of 
one or more of these variables in the diagnosis of cirrhosis.
To analyze agreement between each examiner, kappa values 
were  calculated.  If  there  was  inconsistency  of  the  findings, 
representative values were defined when at least two inspectors 
came to the same conclusion.
Liver biopsy
Liver  biopsies  were  performed  using  a  1.2-mm  Menghini 
needle under informed consent. Tissue was more than at least 
1 cm in length. Liver histology was evaluated semi-quantitatively 
according to the Metavir system. Fibrosis was classified into a 
0~4 scale, as follows: F0, no fibrosis; F1, portal fibrosis; F2, 




SPSS 16.0 was used for the statistical data analysis. To assess 
the diagnostic accuracy of each non-invasive index, receiver-operating 
characteristic  (ROC)  curves  were  constructed  and  the  areas 
under  the  ROC  curves  (AUROC)  were  calculated.  Then,  to 
evaluate the usefulness of the new predictive method, the 
sensitivity,  specificity,  positive  predictive  value  (PPV),  and 
negative predictive value (NPV) were calculated. P values 
< 0.05 were considered statistically significant. 
RESULTS
The  interobserver  agreement  of  ultrasonographic 
findings
Among the three reviewers, the kappa values for agreement of 
surface nodularity between 2 reviewers were 0.279 (P<0.001), 
0.407 (P<0.001), and 0.335 (P<0.001). The kappa coefficients 
were between 0.2 and 0.4, which indicated fair agreement.
The kappa values for the agreement of liver parenchyma echo 
between 2 of 3 reviewers were 0.509 (P<0.001), 0.518 (P<0.001), 
and 0.435 (P<0.001). The kappa coefficients were between 0.4 
and 0.6, which indicated moderate agreement.
Blood  tests  and  ultrasonographic  variables  in  the 
diagnosis of compensated liver cirrhosis
To validate the diagnostic values of non-invasive tests for 
cirrhosis, we calculated the AUROC of each variable (Table 2). 
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Table  4.  Diagnostic  accuracy,  sensitivity,  and  specificity  of  compensated  liver  cirrhosis  by  different  variables
Variables Sensitivity  Specificity  PPV  NPV 
Platelet  (<100,000/uL)  22.22  96.41  57.14  85.19 
Platelet  (<120,000/uL) 41.67  89.22  45.45  87.65 
Albumin  (<3.5  g/dL) 11.11  98.80  66.67  83.76 
INR  (>1.3)  16.67  97.60  60.00  84.46 
Echogenecity  38.89  87.43  40.00  86.90 
Surface  nodularity  33.33  97.01  70.59  87.10 
Spleen  size  (>12  cm)    5.56  86.23    8.00  80.90 
INR,  international  normalized  ratio;  PPV,  positive  predictive  value;  NPV,  negative  predictive  value.
Table  5.  Diagnostic  accuracy,  sensitivity,  and  specificity  of  compensated  liver  cirrhosis  by  combination  of  variables
Variables Sensitivity  Specificity  PPV  NPV 
Surface  nodularity  and  spleen  size    2.78 99.40  50.00  82.59 
Surface  nodularity  and  echogenecity  27.78 97.60  71.43  86.24 
Plt12  or  Alb  or  INR 58.33 86.23 47.73 90.57
Plt10  or  Alb  or  INR 41.67 93.41 57.69 88.14
Surface  nodularity  and  Plt10 16.67 100  100  84.77 
Surface  nodularity  and  Plt10   5.56 100  100  83.08 
Surface  nodularity  and  Alb   2.78 100  100  82.67 
Surface  nodularity  and  INR   8.33 100  100  83.5 
Surface  nodularity  and  (Plt10  or  Alb  or  INR)  13.8 100  100  84.34 
Surface  nodularity  and  (Plt12  or  Alb  or  INR)  22.22 100  100  85.64 
Surface  nodularity  or  Plt10  or  Alb  or  INR  61.11 90.42 57.89  91.52 
Surface  nodularity  or  Plt12  or  Alb  or  INR  69.44 83.23 47.17  92.67 
Surface  nodularity  or  echogenecity  or  Plt10  or  Alb  or  INR  75.00 74.85 39.13  93.28 
> 2
*  among  5  (surface  nodularity,  echogenecity,  Plt10,  Alb,  INR) 38.89   96.41 70.00  87.98 
> 2
*  among  4  (surface  nodularity,  Plt12,  Alb,  INR) 19.44 100  100  85.20 
> 2
*  among  4  (surface  nodularity,  Plt10,  Alb,  INR)   8.33 100  100  83.50 
Plt12,  platelet  (< 120,000/uL);  Plt10, platelet  (< 100,000/uL);  Alb,  albumin  (< 3.5  g/dL);  INR,  INR(> 1.3); PPV, positive  predictive 
value;  NPV,  negative  predictive  value;  2
*, 2  variables.
cirrhosis was 0.503 and the p value of the test was 0.960. Thus, 
cut-off  values  could  not  be  obtained.  Five  variables  were 
identified as predictors of liver cirrhosis. These variables were as 
follows (in increasing order): albumin (P=0.002); INR (P=0.001); 
platelet  count  (P<0.001);  surface  nodularity  (P<0.001);  and 
parenchyma echogenicity (P<0.001). In particular, the AUROC 
value  of  surface  nodularity,  platelet  count,  and  parenchyma 
echogenicity was high (>0.8). 
Logistic regression analysis showed that surface nodularity 
was significantly associated with liver cirrhosis and the odds 
ratio was 12.645. A platelet count <120,000/uL and an albumin 
level <3.5 g/dL had significant odds ratio of 4.575 and 12.409, 
respectively.  The  other  factors  did  not  have  a  significant 
association with the diagnosis of liver cirrhosis (Table 3).
The  usefulness  of  each  variable  in  the  diagnosis 
of compensated liver cirrhosis
To  determine  the  diagnostic  usefulness  of  each  variable, 
cross-analysis was performed (Table 4). The sensitivity of each 
variable had a low range (5.56~41.67%), but the specificity 
was > 85%. A platelet count < 100,000/uL, an albumin level
< 3.5  g/dL,  a  prothrombin  time  (INR) >1.3,  and  surface Hong Sub Lee, et al. Prediction of cirrhosis in chronic hepatitis patients  373
nodularity had a specificity >95%. With a platelet count cut-off 
value <120,000/uL, sensitivity and specificity for the diagnosis 
of  cirrhosis  were  41%  and  89%,  respectively.  Specificity 
increased to 96% and sensitivity decreased to 22% with a platelet 
count cut-off <100,000/uL.
Cross-analysis  was  performed  in  combination  with  high 
specificity variables on the basis of the above results (Table 5). 
The combination of surface nodularity and parenchyma echogenecity 
satisfying two ultrasonographic variables showed a specificity of 
97.6% and a sensitivity of 27.7%. Any 1 of 3 blood variables 
(platelet  count < 100,000/uL,  albumin  level < 3.5  g/dL,  and 
INR>1.3) provided a sensitivity of 41% and a specificity of 
93% for the detection of compensated cirrhosis. The combination 
of surface nodularity and one of the three laboratory variables 
provided 100% of specificity, but low sensitivity (range, 2~22%). 
Based on these findings of at least one of the four variables 
(surface nodularity, platelet counts <100,000/uL, albumin levels
<3.5 g/dL, INR>1.3), cirrhosis was accurately identified with 
90% specificity and 61% sensitivity. With a platelet cut off value 
of 120,000/uL, the sensitivity increased to 69% but specificity 
decreased to 83%. And the combinations satisfying two among 
many variables showed 40% or less of sensitivity.
DISCUSSION
Early diagnosis of liver cirrhosis in chronic hepatitis patients 
is critical because it can predict and reduce complications of 
cirrhosis and the occurrence of hepatocellular carcinoma. Guidelines 
for  the  diagnosis  of  compensated  liver  cirrhosis  are  rarely 
reported worldwide.
15 In the absence of specific non-invasive 
diagnostic guidelines, clinicians use a variety of criteria. It is 
considered that these phenomena are caused by the limitations of 
non-invasive  methods  in  the  diagnosis  of  liver  cirrhosis. 
Therefore, non-invasive diagnostic instructions of liver cirrhosis 
are very important to treat the patients and perform the research. 
For a non-invasive diagnosis of cirrhosis, ideal conditions 
require that the results are reliable, diagnostic tools are easy to 
perform,  are  inexpensive  and  commonly  used,  and  deemed 
worthy  by  a  number  of  checks.
16  Methods  satisfying  these 
conditions include ultrasonographic imaging and blood tests. In 
the diagnosis of compensated liver cirrhosis, liver biopsy is the 
most accurate diagnostic method. However, a liver biopsy is 
performed in few patients in clinical practice. In most patients, 
the blood tests and abdominal ultrasonography are performed to 
diagnose  compensated liver  cirrhosis. The accuracy of these 
non-invasive diagnostic tests can vary depending on the physician. 
In addition to ultrasonographic imaging, computed tomography 
and  nuclear  magnetic  resonance  imaging  have  been  used  to 
diagnose cirrhosis in some studies, but there was no distinct 
advantage over ultrasonography, and computed tomography and 
nuclear magnetic resonance imaging was not generally available.
17
Because  ultrasonography  has  been  widely  used  for  the 
observation of chronic hepatitis and hepatocellular carcinoma 
screening,  the  role  of  abdominal  ultrasonography  has  been 
reported in the diagnosis of compensated cirrhosis. Gaiani et al.
18 
investigated the accuracy of an ultrasonographic score derived 
from liver, spleen, and portal vein features in predicting the final 
diagnosis in 212 patients with compensated chronic liver disease 
undergoing  percutaneous  liver  biopsy.  They  identified  liver 
surface nodularity and portal flow velocity as factors independently 
associated with cirrhosis (p<0.005), and a score based on these 
two variables correctly identified cirrhosis in 82.2% of cases 
(82.2% sensitivity and 79.9% specificity). Liver surface nodularity 
was associated with the diagnosis of cirrhosis in other studies.
19-21 
Enlargement of the caudate lobe had a high specificity, but low 
sensitivity (26~41%). Spleen size and echogenicity pattern also 
had  a  high  specificity,  but  low  sensitivity  for  diagnosing 
cirrhosis.
20,21
In the current study, the ultrasonographic findings, such as 
liver surface nodularity, internal echogenicity pattern, and spleen 
size, were compared with pathologically-confirmed liver cirrhosis. 
In agreement with previous studies, liver surface nodularity had 
very  high  specificity  (97%),  but  low  sensitivity  (33%).  The 
sensitivity and specificity of the other two variables were lower 
than those of liver surface nodularity. The role of ultrasonographic 
examination in the diagnosis of early cirrhosis is limited due to 
low specificity, although sonographic variables could be combined. 
Therefore, ultrasonographic findings alone are insufficient as a 
screening test for liver cirrhosis.
22
In addition to ultrasonography, there are many non-invasive 
methods using blood tests to diagnose liver cirrhosis. The serum 
fibrosis markers can be divided into direct and indirect markers. 
Direct markers are involved in the formation of extracellular 
matrix  during  fibrosis,  and  indirect  markers  reflect  hepatic 
dysfunction. Several studies on the diagnosis of liver cirrhosis 
using direct fibrosis markers, such as collagen and hyaluronic 
acid, had a low sensitivity and specificity (approximately 80%), 
and fibrosis markers are expensive and not available in clinical 
practice.
23-25  Indirect  fibrosis  markers  include  an  indirect 
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(APRI),  Forn's  index,  and  FIB-4.  However,  indirect  fibrosis 
markers were not sufficient as a single indicator in diagnosing 
liver cirrhosis in many studies.
11,26-28
Sebastian et al. published results showing that a fibroscan and 
blood tests can reduce the liver biopsy, but a fibroscan is an 
expensive piece of equipment. A fibroscan is not available for 
obese patients, and is not available for clinical practice.
16
We evaluated the diagnostic accuracy of ultrasonography and 
routine blood tests in the diagnosis of compensated cirrhosis and 
established the diagnostic criteria. We investigated the diagnostic 
accuracy  of  the  model  consisting  of  four  variables  (surface 
nodularity, platelet count, albumin level, and INR). Based on the 
findings  of  at  least  one  of  the  four  variables,  we  identified 
cirrhosis  accurately  (90%  specificity  and  61%  sensitivity). 
Variables  used  in  this  study  included  serum  albumin  and 
prothrombin time (INR) indicating the protein synthetic activity 
of liver and platelet count, reflecting portal hypertension. As 
these  variables,  except  the  platelet  count,  are  used  in  the 
Child-Pugh classification, the specificity of the items appears to 
be high.
The albumin level and INR had>95% specificity in identifying 
cirrhosis, but the sensitivity was very low. The platelet count had 
better sensitivity while maintaining high specificity compared to 
the albumin level and INR. A platelet count <100,000/uL has 
been widely accepted as the cut-off level of portal hypertension.
29 
In this study, a platelet count <100,000/uL had 22% sensitivity 
and  96%  specificity  in  identifying  compensated  cirrhosis. 
When we defined a platelet count cut-off of <1,200,000/uL, 
the  sensitivity  increased  to  41%  with  a  minor  reduction  in 
specificity (89%).
This study has several strengths. First, liver cirrhosis can be 
predicted without special equipment in any hospital. Second, 
three experienced physicians reviewed ultrasonographic findings 
of 30 patients to objectify the subjective sonographic findings. 
Third, we suggested the standard criteria which are not unified in 
diagnosing liver cirrhosis on the basis of Korean data.
However, this study had several limitations. First, a retrospective 
study may have a bias in selecting patients and the number of 
patients  was  relatively  small.  Second,  the  study  design  was 
cross-sectional. The results of blood tests can vary depending on 
the patient condition. Thus, sequential measurements or mean 
values would be better as a representative value.
In  conclusion,  the  model  consisting of  surface nodularity, 
platelet count < 100,000/uL, albumin level < 3.5 g/dL, and 
prothrombin time (INR) >1.3 may be useful for the identification 
of compensated cirrhosis with a high degree of accuracy in daily 
practice. 
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